{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:49:09Z","timestamp":1769165349108,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI13\/01012"],"award-info":[{"award-number":["PI13\/01012"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.thromres.2019.01.021","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T02:59:12Z","timestamp":1548903552000},"page":"95-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["High and low on-treatment platelet reactivity to P2Y12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention"],"prefix":"10.1016","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1202-9575","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Ferreiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Vivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Mar\u00eda","family":"De La Hera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Lucrecia","family":"Marcano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie Marisol","family":"Lugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"G\u00f3mez-Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iria","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Tello-Montoliu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7246-7708","authenticated-orcid":false,"given":"Francisco","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2019.01.021_bb0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J."},{"key":"10.1016\/j.thromres.2019.01.021_bb0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0300-8932(10)70010-5","article-title":"Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions","volume":"63","author":"Angiolillo","year":"2010","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.thromres.2019.01.021_bb0015","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2019.01.021_bb0020","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2019.01.021_bb0025","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2019.01.021_bb0030","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2019.01.021_bb0035","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2019.01.021_bb0040","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2019.01.021_bb0045","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2019.01.021_bb0050","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1055\/s-0035-1570083","article-title":"Platelet function testing in patients on antiplatelet medications","volume":"42","author":"Gross","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2019.01.021_bb0055","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","author":"Campo","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.thromres.2019.01.021_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12265-013-9533-5","article-title":"Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation","volume":"7","author":"Ferreiro","year":"2014","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.thromres.2019.01.021_bb0065","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11239-012-0846-z","article-title":"Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation","volume":"35","author":"Ferreiro","year":"2013","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2019.01.021_bb0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1160\/TH07-07-0478","article-title":"Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment","volume":"99","author":"Sibbing","year":"2008","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.01.021_bb0075","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2019.01.021_bb0080","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.thromres.2019.01.021_bb0085","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008125","article-title":"Ticagrelor use in acute myocardial infarction: insights from the national cardiovascular data registry","volume":"7","author":"Basra","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2019.01.021_bb0090","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel","volume":"10","author":"Bonello","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.01.021_bb0095","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/CIRCULATIONAHA.116.023402","article-title":"Pharmacodynamic comparison of Prasugrel versus Ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (optimizing antiplatelet therapy in diabetes mellitus)-4 study","volume":"134","author":"Franchi","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2019.01.021_bb0100","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1160\/TH14-02-0119","article-title":"Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events","volume":"112","author":"Alexopoulos","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.01.021_bb0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1160\/TH13-01-0057","article-title":"Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery","volume":"110","author":"Ferreiro","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.01.021_bb0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ehjcvp\/pvw026","article-title":"Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients","volume":"3","author":"Vries","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.thromres.2019.01.021_bb0115","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/00365513.2017.1286686","article-title":"Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and multiplate assays","volume":"77","author":"Danielak","year":"2017","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.thromres.2019.01.021_bb0120","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000849","article-title":"Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry","volume":"3","author":"Sherwood","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2019.01.021_bb0125","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2019.01.021_bb0130","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2019.01.021_bb0135","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2019.01.021_bb0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ahj.2016.09.006","article-title":"Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study","volume":"182","author":"Baber","year":"2016","journal-title":"Am. Heart J."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819300301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819300301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:38:38Z","timestamp":1758735518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384819300301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":28,"alternative-id":["S0049384819300301"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2019.01.021","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High and low on-treatment platelet reactivity to P2Y12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2019.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}